Konduri G Ganesh
Division of Neonatology, Medical College of Wisconsin and Children's Research Institute of Children's Hospital of Wisconsin, MS 213 A, Milwaukee, WI 53226, USA.
Clin Perinatol. 2004 Sep;31(3):591-611. doi: 10.1016/j.clp.2004.04.001.
The management of PPHN entered a new era with the development of inhaled NO therapy for the relief of pulmonary hypertension. The wider application of INO therapy and improved ventilation strategies led to a decrease in the need for invasive life-sustaining therapies such as ECMO. The remarkable advances in the understanding and treatment of PPHN were made possible by the extensive investigations in the laboratory using animal models. Further decreases in morbidity and mortality are possible with specific strategies targeted to correct the alterations in NO and prostacyclin biology and strategies to reduce lung injury. Further research is needed to understand the basis for the biologic susceptibility of some infants to environmental insults such as intra-uterine stressor exposure to NSAIDs in utero.
随着用于缓解肺动脉高压的吸入一氧化氮（NO）疗法的发展，持续性肺动脉高压（PPHN）的治疗进入了一个新时代。INO疗法的更广泛应用和改进的通气策略导致对诸如体外膜肺氧合（ECMO）等侵入性维持生命疗法的需求减少。通过在实验室使用动物模型进行的广泛研究，使我们对PPHN的理解和治疗取得了显著进展。通过针对纠正NO和前列环素生物学改变的特定策略以及减少肺损伤的策略，有可能进一步降低发病率和死亡率。需要进一步研究以了解一些婴儿对环境损伤（如子宫内应激源暴露、子宫内接触非甾体抗炎药）的生物易感性的基础。
